M&A / Deals AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid Pharmaceutical TechnologyAbbVie's deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries.M&A / DealsPain & AnaesthesiaRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology AbbVie’s deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries. M&A / DealsPain & AnaesthesiaRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA issues complete response letter to Replimune’s RP1 for melanomaNext: AbbVie enters world of pain in up to $715M deal with China’s Haisco Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
